TGFB1 and pulmonary fibrosis: Moreover, a recent study by Landi et al., demonstrated that nintedanib, one of two FDA approved anti-fibrotic drugs, modulates TGF-β, VEGF, and Wnt/β-catenin signaling pathways, supporting the central role of these pathways in pulmonary fibrosis development [154].